369 related articles for article (PubMed ID: 16257440)
41. 18F-FDG PET in the management of endometrial cancer.
Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
[TBL] [Abstract][Full Text] [Related]
42. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy.
Xue F; Lin LL; Dehdashti F; Miller TR; Siegel BA; Grigsby PW
Gynecol Oncol; 2006 Apr; 101(1):147-51. PubMed ID: 16263155
[TBL] [Abstract][Full Text] [Related]
43. Defining the priority of using 18F-FDG PET for recurrent cervical cancer.
Yen TC; See LC; Chang TC; Huang KG; Ng KK; Tang SG; Chang YC; Hsueh S; Tsai CS; Hong JH; Lin CT; Chao A; Ma SY; Lin WJ; Fu YK; Fan CC; Lai CH
J Nucl Med; 2004 Oct; 45(10):1632-9. PubMed ID: 15471826
[TBL] [Abstract][Full Text] [Related]
44. [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up].
Hu YY; Sun XR; Lin XP; Liang PY; Zhang X; Fan W
Ai Zheng; 2009 Sep; 28(9):994-9. PubMed ID: 19728921
[TBL] [Abstract][Full Text] [Related]
45. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
[TBL] [Abstract][Full Text] [Related]
46. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
47. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer.
Lin LL; Yang Z; Mutic S; Miller TR; Grigsby PW
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):177-81. PubMed ID: 16545921
[TBL] [Abstract][Full Text] [Related]
48. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
49. FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI.
Stojiljkovic M; Sobic Saranovic D; Odalovic S; Popovic M; Petrovic J; Rankovic N; Veljkovic M; Artiko V
Radiol Oncol; 2022 Dec; 56(4):453-460. PubMed ID: 36317553
[TBL] [Abstract][Full Text] [Related]
50. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
[TBL] [Abstract][Full Text] [Related]
51. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
52. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.
Unger JB; Ivy JJ; Connor P; Charrier A; Ramaswamy MR; Ampil FL; Monsour RP
Gynecol Oncol; 2004 Jul; 94(1):212-6. PubMed ID: 15262145
[TBL] [Abstract][Full Text] [Related]
53. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
54. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
Brooks RA; Rader JS; Dehdashti F; Mutch DG; Powell MA; Thaker PH; Siegel BA; Grigsby PW
Gynecol Oncol; 2009 Jan; 112(1):104-9. PubMed ID: 18929403
[TBL] [Abstract][Full Text] [Related]
55. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.
Yildirim Y; Sehirali S; Avci ME; Yilmaz C; Ertopcu K; Tinar S; Duman Y; Sayhan S
Gynecol Oncol; 2008 Jan; 108(1):154-9. PubMed ID: 17945337
[TBL] [Abstract][Full Text] [Related]
56. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutic S; Mutch DG; Powell MA; Grigsby PW
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1085-91. PubMed ID: 19880262
[TBL] [Abstract][Full Text] [Related]
57. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
[TBL] [Abstract][Full Text] [Related]
58. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy.
Sharma DN; Rath GK; Kumar R; Malhotra A; Kumar S; Pandjatcharam J; Maharjan S
J Cancer Res Ther; 2012; 8(1):23-7. PubMed ID: 22531509
[TBL] [Abstract][Full Text] [Related]
59. The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up.
Lin SY; Tsai CS; Chang YC; Ng KK; Chang TC; Kao WH; Lai CH; Hong JH
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):577-85. PubMed ID: 25936817
[TBL] [Abstract][Full Text] [Related]
60. Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer.
Lai AYT; Perucho JAU; Xu X; Hui ES; Lee EYP
BMC Cancer; 2017 Dec; 17(1):825. PubMed ID: 29207964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
